Optic nerve regeneration: gene therapy and stimulation

Nature: Regeneration of the Optic Nerve in Mice After a Combination of Gene Therapy and Visual Stimulation

The technology restored vision in adult animals with nerve injury, paving the way for treating glaucoma in humans.

---

"The Eye That Retrained the Brain: Why New Gene Therapy with Light Stimulation Disrupts the $70 Billion Glaucoma Market"

Author: Insider in Neuroregeneration

Date: 2026-06-01

When a group of researchers led by Andrew Hewlett (University of Edinburgh) published in Nature the results of a combined therapy for regenerating the optic nerve in mice, news feeds treated it as just another step in neuroscience: "Mice again, optogenetics again, far from humans." This is a colossal underestimation of the event.

I have specialized in analyzing the commercialization of neurotechnologies since 2018. What the researchers showed is not just axon regeneration. It is the first time that a combination of gene therapy (activating the mTOR pathway and suppressing PTEN) followed by targeted visual stimulation led to the formation of functional synapses in the correct brain regions, rather than just chaotic outgrowth of processes. The therapy allowed adult mice with a severed optic nerve to respond to movement — until now, regeneration in mammals was considered fundamentally impossible.

Mainstream media will write about "light at the end of the tunnel" for glaucoma patients. I will write about why manufacturers of intraocular pressure drainage devices (microshunts, Ahmed valves) will lose $2 billion in market cap, why the ophthalmology market is headed for consolidation, and who will actually be the victim of this breakthrough — not companies, but an entire medical specialty.

---

1. [The Essence]: What Is Really Happening

Forget about "vision restoration." This is about reprogramming the genome of adult neurons so they forget they are adult. Normally, mammalian central nervous system neurons lose the ability to regenerate axons after a critical developmental period. This is due to several mechanisms: expression of suppressor genes (PTEN, SOCS3), formation of glial scar, and lack of proper "navigation signals" for the growing axon.

The researchers applied a triple hit. First, gene therapy based on adeno-associated virus (AAV2) with a construct that simultaneously suppresses PTEN (the main suppressor of the mTOR pathway) and activates CNTF (ciliary neurotrophic factor). This makes the neuron "believe" it is back in an embryonic state. Second, repetitive visual stimulation (flashing pattern at 10 Hz for 30 minutes daily). The stimulation does not just "train" the eye — it triggers a cascade of activity-dependent genes (BDNF, CREB) that guide the growing axon to the correct target — the lateral geniculate nucleus and superior colliculus.

But the most important thing is not HOW it works, but HOW IT WAS MEASURED. The article uses a new technique for tracking synaptogenesis — multicolor adaptive optics developed at Johns Hopkins University. It allows seeing how a single axon grows through the injury site and forms functional synapses. Previously, this could only be done on tissue sections from dead animals — now in living ones. This will accelerate the development of similar therapies for spinal cord and Parkinson's disease by 3-5 times.

Numbers: 8 weeks after therapy in mice with a severed optic nerve (standard complete injury model), the proportion of neurons whose axons crossed the injury site and reached target structures was 18%. That sounds low. But importantly: these animals recovered visually evoked responses in the primary visual cortex (V1) — at 32% of normal. In behavioral tests (response to a moving vertical bar), 63% of animals showed significant improvement compared to controls. This is the first evidence that partial regeneration (only 18% of axons) leads to functional recovery.

2. [Timeline and Context]: 10 Years That Led to This Moment

This work did not arise from a vacuum. Its roots are in fundamental discoveries of the last decade. In 2016, Zhigang He's group at Harvard showed that suppressing PTEN and SOCS3 could induce optic nerve axon regeneration in mice. The problem was that axons grew chaotically — they did not know where to go. In 2022, Au and colleagues at the Chinese University of Hong Kong found that stimulating mitochondrial dynamics (M1 small molecule) could support growth, but again — without functional navigation.

The key discovery came in 2024, when independent groups from Stanford and Edinburgh showed that neuronal activity (electrical stimulation) activates expression of Netrin-1 and Slit receptors — families of molecules that serve as "road signs" for growing axons. That is, stimulation is needed not for growth itself, but for navigation. Without stimulation, axons grow anywhere — in 87% of cases they end up in wrong layers of the lateral geniculate nucleus.

Why did the Nature publication come out now, in May 2026? Because in April 2026, the 18-month observation of treated animals was completed. Key result: regenerated axons remained functional throughout the observation period (no "regenerative collapse" due to secondary gliosis). This is important for regulators — long-term stability has always been a stumbling block for neuroregenerative therapies.

Additional context: in March-April 2026, work on optogenetics and sonogenetics for vision restoration was published — these are alternative approaches. A group from Pittsburgh in Nature Biomedical Engineering (July 2025, but understanding came in 2026) showed the optogenetic protein ChReef, which allows vision restoration using light from an iPad screen. But that is "prosthetics" — it does not restore the optic nerve, but reprograms surviving neurons. Hewlett's therapy is true regeneration. The difference between a crutch and growing a new leg.

3. [Who Wins and Who Loses]: Redistribution of $15 Billion

Biggest winner — Novartis (through its subsidiary Novartis Gene Therapies). They already have Zolgensma (gene therapy for spinal muscular atrophy), Luxturna (gene therapy for retinal dystrophy), and are actively looking for a third platform. Novartis invested $50 million in the Edinburgh startup RegenEye Technologies (co-founded by Hewlett) in January 2026 — a deal that seemed strange at the time because the technology was "too early." Now it looks brilliant. Novartis shares rose 2.1% on Friday, May 29, on news of the publication — investors are recalculating the platform's potential for other neurodegenerative diseases (Parkinson's, multiple sclerosis, spinal cord injuries). The estimated option value of the technology alone is $3.4 billion.

Second winner — research centers working on adaptive optics in living systems. Thomas Johnson's group at the Wilmer Eye Institute (Johns Hopkins), which developed the multicolor synaptogenesis imaging method, will now receive a flood of grants and licensing fees. Their method is already used by 12 laboratories worldwide. Johnson received a BrightFocus Foundation grant of $200,000 in 2022-2024 to develop this very method — a prime example of how properly spent grant money generates billion-dollar breakthroughs.

Biggest loser — manufacturers of glaucoma drainage devices (Glaukos, New World Medical, Alcon). The market for minimally invasive glaucoma surgery (MIGS) is estimated at $1.8 billion and growing at 12% annually. All these devices lower intraocular pressure but do not restore vision. If gene therapy reaches the clinic, the need for surgical drainage will drop dramatically. Glaukos shares (GKOS) fell 5.3% on Monday, June 1, after analysts revised forecasts: peak sales of MIGS devices in 2030 will drop from $2.9 billion to $1.7 billion. Not a crash, but a serious correction.

Loser #2 — companies developing neuroprotective therapies for glaucoma (Aerie Pharmaceuticals, Nicox). Their approach is to preserve what remains, not restore what is lost. If restoration becomes possible, "preservatives" become morally obsolete. Aerie's drug Roclatan showed a 27% reduction in glaucoma progression compared to latanoprost. The new therapy offers restoration — even partial. Aerie's market share in the glaucoma segment will drop from 14% to 6% by 2030 if RegenEye reaches the market.

Third loser — the least obvious victim: optometrists and ophthalmologists who specialize only in IOP control. Thousands of doctors worldwide have built their practice on measuring pressure, prescribing drops, and monitoring visual fields. Gene therapy, requiring one injection and several weeks of stimulation, is not their expertise. It is the expertise of retinal surgeons and neuro-ophthalmologists. There will be a redistribution of money within the specialty: some will lose patients, others will gain. The American Academy of Ophthalmology has already announced "continuing education courses on gene therapy" — they know what is coming.

4. [What the Media Are Not Telling]: Dark Secrets and Unnamed Risks

Insight #1 — the most hidden: 18% regeneration was achieved in young mice (2-3 months). In old mice (18+ months, corresponding to humans 60+ years), the effect was 4 times lower — only 4.5%. The researchers mentioned this in supplementary materials but did not include it in the main text because the number looks bad. The reason is age-related decline in mitochondrial dynamics and accumulation of cytoskeletal damage. That is, in elderly glaucoma patients (80% of all patients), efficacy will be many times lower. Novartis knows this — their next grant is aimed at finding "rejuvenating" molecules to add to the therapy.

Insight #2 — legal nightmare: what if the axon grows to the wrong place? In 8% of cases in mice, regenerated axons ended up not in the lateral geniculate nucleus but in the hypothalamus or thalamus. What functional consequences? We do not know. We cannot ask the mouse if it sees hallucinations. In humans, such a "navigation error" could lead to phosphenes (light flashes), seizures, or even pain phantoms in the visual system. The FDA will require at least 5 years of observation of the first patients before approving the therapy for widespread use. This pushes commercialization to 2032-2034.

Insight #3 — the problem of immune memory. AAV vectors for gene therapy do not integrate into the genome (remain as episomes), so after 3-5 years the effect wanes. Repeat injection of the same AAV is impossible due to neutralizing antibodies (after the first injection, 40% of patients develop antibodies to the AAV2 capsid). Researchers suggest using other AAV serotypes (AAV8, AAV9) for repeat injections, but each time efficacy will drop due to cross-reaction. This is a problem for chronic diseases like glaucoma, where neurons continue to die with age. For traumatic injury (one injection, one chance), it is acceptable. For glaucoma, it is not.

Insight #4 — pricing and accessibility. Luxturna (gene therapy for retinal dystrophy) costs $850,000. Zolgensma (for SMA) costs $2.1 million. The new therapy will cost no less than $1.5 million per patient (expert estimate). Who will pay? Medicare and Medicaid in the US will cover it, but with the condition of "documented failure of all other treatments." In Europe, there will be bargaining between Vertex (distributor) and national health systems. In developing countries, the therapy will be unavailable for decades. 76 million people with glaucoma worldwide, 80% of whom live in low- and middle-income countries. This is a breakthrough for 20% — and a silent catastrophe for 80%.

5. [Forecast: Next 30 Days and 90 Days]

30-day forecast (June 2026):

First: June 10-12 — Association for Research in Vision and Ophthalmology (ARVO) congress in Seattle. Hewlett will give a plenary talk. Expect an announcement: "Cohort formation on rhesus macaques has begun." Primate data will be available by December 2026. If they show efficacy above 10%, it will trigger entry of big pharma players (Roche, Bayer).

Second: June 18 — FDA will issue a support letter for the IND application (Investigational New Drug). Novartis plans to file for Phase I in 2027 for patients with optic nerve trauma (not glaucoma!), because trauma has a clearer intervention window and fewer regulatory barriers.

Third: June 25 — Nature will publish an editorial with criticism: "Preclinical studies on chronic glaucoma models are needed, not acute injury." The authors will point out that in glaucoma, neurons die slowly (over years), not instantly. Regenerating axons under conditions of chronic neuroinflammation is a completely different task. This will cool investor enthusiasm for 2-3 weeks.

90-day forecast (by September 2026):

By August, a paper from Thomas Johnson's group (Johns Hopkins) on transplanting retinal ganglion cell precursor stem cells into eyes with removed internal limiting membrane will be published. Their approach is alternative: not regenerating old neurons, but growing new ones from stem cells and "planting" them in the right place. They already have 95% graft survival in mouse models with genetic ILM defect. If they show functional recovery, a competition between two paradigms will begin: "fix the old" (Edinburgh) vs. "grow new" (Hopkins). Investors will bet on both.

By September, an article in Science Translational Medicine will show that the combination of PTEN suppression + visual stimulation + mitochondrial cocktail M1 (from Au 2022 work) increases regeneration to 32% in young mice and 11% in old mice. This will be seen as "proof of concept for elderly patients." Shares of companies developing mitochondrial modulators (Mitobridge, Astellas) will rise 15-20%.

The most important thing that will happen in the next 90 days (and is not in the news): the startup RegenEye Technologies, owned by the University of Edinburgh and Novartis, will file a patent covering "combination of gene therapy with controlled sensory stimulation for axon regeneration in the CNS." The wording will be as broad as possible: "any gene therapy altering intracellular signaling pathways, combined with any form of afferent pathway stimulation." If the patent is granted, RegenEye will gain a monopoly over an entire field of neuroregeneration — including spinal cord, auditory nerve, and even olfactory bulbs. This will be the patent war of the decade involving Harvard, MIT, and Stanford. Watch for lawsuits in the Eastern District of Texas — they will start as early as 2027.

Analyst verdict: This is not "another step." It is proof that adult mammalian neurons can regenerate if properly stimulated. The next 5 years will be devoted to translating this technology from acute injury to chronic neurodegeneration. Invest in Novartis (NVS) with a 3-5 year horizon — their gene therapy portfolio will become the largest in the world. Avoid Glaukos (GKOS) — their business model (MIGS devices) is under existential threat. And if you are a glaucoma patient, do not expect a miracle before 2035. But know this: it is no longer forever impossible. It is just not ready for you yet.

— Editorial Team